Loading clinical trials...
Loading clinical trials...
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of Rocatinlimab on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)
Conditions
Interventions
Rocatinlimab
Placebo
Locations
85
United States
Affiliated Dermatology
Scottsdale, Arizona, United States
Center for Dermatology and Plastic Surgery
Scottsdale, Arizona, United States
Scottsdale Clinical Trials
Scottsdale, Arizona, United States
Medical Advancement Centers of Arizona
Tempe, Arizona, United States
Little Rock Allergy and Asthma Clinical Research Center
Little Rock, Arkansas, United States
Kern Research Inc
Bakersfield, California, United States
Start Date
June 7, 2023
Primary Completion Date
August 26, 2024
Completion Date
November 14, 2024
Last Updated
November 5, 2025
NCT07217015
NCT06116526
NCT06461897
NCT07262983
NCT06389136
NCT06342713
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions